edaravone has been researched along with Respiratory Distress Syndrome in 3 studies
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pulmonary fibrosis is responsible for the both short-term and long-term outcomes in patients with acute respiratory distress syndrome (ARDS)." | 5.48 | Edaravone attenuates lipopolysaccharide-induced acute respiratory distress syndrome associated early pulmonary fibrosis via amelioration of oxidative stress and transforming growth factor-β1/Smad3 signaling. ( Chen, G; Lai, R; Liang, Z; Su, X; Wang, X, 2018) |
| "Edaravone treatment decreased the neutrophil infiltration, the lipid membrane peroxidation, and the expression of proinflammatory cytokine interleukin-6 mRNA in the lungs after intestinal I/R compared to the I/R-treated rat lungs without edaravone treatment." | 5.33 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. ( Horikawa, S; Ito, K; Ozasa, H, 2005) |
| "Pulmonary fibrosis is responsible for the both short-term and long-term outcomes in patients with acute respiratory distress syndrome (ARDS)." | 1.48 | Edaravone attenuates lipopolysaccharide-induced acute respiratory distress syndrome associated early pulmonary fibrosis via amelioration of oxidative stress and transforming growth factor-β1/Smad3 signaling. ( Chen, G; Lai, R; Liang, Z; Su, X; Wang, X, 2018) |
| "Edaravone treatment decreased the neutrophil infiltration, the lipid membrane peroxidation, and the expression of proinflammatory cytokine interleukin-6 mRNA in the lungs after intestinal I/R compared to the I/R-treated rat lungs without edaravone treatment." | 1.33 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. ( Horikawa, S; Ito, K; Ozasa, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Lai, R | 1 |
| Su, X | 1 |
| Chen, G | 1 |
| Liang, Z | 1 |
| Kono, H | 1 |
| Asakawa, M | 1 |
| Fujii, H | 1 |
| Maki, A | 1 |
| Amemiya, H | 1 |
| Yamamoto, M | 1 |
| Matsuda, M | 1 |
| Matsumoto, Y | 1 |
| Ito, K | 1 |
| Ozasa, H | 1 |
| Horikawa, S | 1 |
3 other studies available for edaravone and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Edaravone attenuates lipopolysaccharide-induced acute respiratory distress syndrome associated early pulmonary fibrosis via amelioration of oxidative stress and transforming growth factor-β1/Smad3 signaling.
Topics: Animals; Antipyrine; Dose-Response Relationship, Drug; Edaravone; Free Radical Scavengers; Lipopolys | 2018 |
Edaravone, a novel free radical scavenger, prevents liver injury and mortality in rats administered endotoxin.
Topics: Alanine Transaminase; Animals; Antipyrine; Chemokine CCL4; Chemokines; Chemokines, CC; Chemokines, C | 2003 |
Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat.
Topics: Animals; Antipyrine; Disease Progression; Edaravone; Interleukin-6; Intestines; Ischemia; Lung; Male | 2005 |